Q/C Technologies, Inc. (0A8D)

Overview

TNF Pharmaceuticals, Inc. is a pioneering clinical stage pharmaceutical company dedicated to reshaping the landscape of healthcare through novel therapeutic solutions. The company's mission is to tackle the root causes of diseases by developing innovative treatments that extend beyond merely alleviating symptoms. Established in 2014 and based in Baltimore, Maryland, TNF Pharmaceuticals, formerly known as MyMD Pharmaceuticals, Inc., demonstrates its commitment to leading-edge science and patient care. With a focus on harnessing the power of the immune system and addressing the growing market for cannabis-based therapies, TNF Pharmaceuticals is at the forefront of creating groundbreaking drugs aimed at enhancing longevity, improving quality of life, and revolutionizing treatment for autoimmune diseases, chronic pain, addiction, and epilepsy.

Products and Services

• MYMD-1

MYMD-1 stands as TNF Pharmaceuticals' premier drug platform, representing a significant breakthrough in the field of pharmaceuticals. This clinical-stage small molecule is designed to modulate the immune system, primarily targeting TNF-alpha, a critical factor in chronic inflammation and other pro-inflammatory cytokines. Through its regulation of these elements, MYMD-1 aims to combat the aging process, potentially extending longevity and providing a new avenue for the treatment of various autoimmune diseases. Its development underscores TNF Pharmaceuticals' dedication to innovative healthcare solutions that promise to transform the lives of patients worldwide.

• Supera-CBD

In response to the burgeoning demand for effective, non-opioid treatments for chronic pain, addiction, and epilepsy, TNF Pharmaceuticals is advancing Supera-CBD. This novel synthetic derivative of cannabidiol (CBD) encapsulates the company's effort to refine and enhance the therapeutic potentials of CBD. Supera-CBD is positioned to elevate the standard for cannabis-based treatments, aiming to surmount the limitations of current FDA-approved drugs and non-regulated CBD products. By developing Supera-CBD, TNF Pharmaceuticals not only seeks to pioneer advancements in the CBD market but also to deliver safer, more reliable options for patients grappling with pain, addiction, and epileptic disorders.